natgillin/translations-raw huggingface dataset:
Daratumumab has not been studied in patients with moderate (TB &gt; 1.5 x to 3 x ULN and any AST) or severe (TB &gt; 3 x ULN and any AST) hepatic impairment.
Daratumumab se nije ispitivao u bolesnika s umjerenim (ukupni bilirubin &gt; 1,5 – 3 x GGN i bilo koja vrijednost AST-a) ni teškim (ukupni bilirubin &gt; 3 x GGN i bilo koja vrijednost AST-a) oštećenjem jetrene funkcije.
Daratumumab has not been studied in patients with moderate to severe hepatic impairment (TB &gt; 1.5 x ULN and any AST), therefore no dose recommendations can be made in these patient populations (see section 5.2).
Daratumumab se nije ispitivao u bolesnika s umjerenim do teškim oštećenjem jetrene funkcije (ukupni bilirubin &gt; 1,5 x GGN i bilo koja vrijednost AST-a), pa se ne mogu dati preporuke za doziranje u tim populacijama bolesnika (vidjeti dio 5.2).
Darunavir demonstrates antiviral activity in vitro against a broad panel of HIV-1 group M (A, B, C, D, E, F, G) and group O primary isolates with EC50 values ranging from &lt; 0.1 to 4.3 nM.
Darunavir pokazuje antivirusnu aktivnost in vitro protiv širokog panela HIV-1 skupine M (A, B, C, D, E, F, G) i skupine O primarno izolata s EC50 vrijednostima u rasponu od &lt; 0,1 do 4,3 nM.
Data are not available for the use of PegIntron in patients with creatinine clearance &lt; 15 ml/minute (see section 5.2).
Nema podataka o primjeni lijeka PegIntron u bolesnika s klirensom kreatinina &lt; 15 ml/min (vidjeti dio 5.2).
Data are not available for the use of ViraferonPeg in patients with creatinine clearance &lt; 15 ml/minute (see section 5.2).
Nema podataka o primjeni lijeka ViraferonPeg u bolesnika s klirensom kreatinina &lt; 15 ml/min (vidjeti dio 5.2).
Data from a multicenter open label randomized study support the use of docetaxel for the adjuvant treatment of patients with operable node-positive breast cancer and KPS ≥ 80%, between 18 and 70 years of age.
Podaci iz multicentričnog, otvorenog, randomiziranog ispitivanja podupiru primjenu docetaksela za adjuvantno liječenje bolesnika s operabilnim karcinomom dojke i pozitivnim limfnim čvorovima te s KPS &gt; 80%, u dobi od 18 do 70 godina.
Data from a multicenter open label randomized study support the use of docetaxel for the adjuvant treatment of patients with operable node-positive breast cancer and KPS ≥ 80%, between 18 and 70 years of age.
Podaci iz multicentričnog, otvorenog, randomiziranog kliničkog ispitivanja podupiru primjenu docetaksela za adjuvantno liječenje bolesnika s operabilnim karcinomom dojke i pozitivnim limfnim čvorovima te s KPS &gt; 80%, u dobi od 18 do 70 godina.
Data from a multicenter open label randomized study support the use of docetaxel for the adjuvant treatment of patients with operable node-positive breast cancer and KPS ≥80%, between 18 and 70 years of age.
Podaci iz multicentričnog, otvorenog, randomiziranog ispitivanja podupiru primjenu docetaksela za adjuvantno liječenje bolesnika s operabilnim karcinomom dojke i pozitivnim limfnim čvorovima te s KPS &gt; 80%, u dobi od 18 do 70 godina.
Data from a multicenter open label randomized study support the use of docetaxel for the adjuvant treatment of patients with operable node-positive breast cancer and KPS  80%, between 18 and 70 years of age.
Podaci iz multicentričnog, otvorenog, randomiziranog ispitivanja podupiru primjenu docetaksela za adjuvantno liječenje bolesnika s operabilnim karcinomom dojke i pozitivnim limfnim čvorovima te s KPS &gt; 80%, u dobi od 18 do 70 godina.
Data from an open label clinical trial suggest that large tumours ( &gt; 7.25 cm2) are less likely to respond to imiquimod therapy.
Podaci iz otvorenog kliničkog ispitivanja upućuju na činjenicu da će veliki tumori ( &gt; 7,25 cm2) vjerojatno slabije reagirati na terapiju imikvimodom.
Data from the pooled safety database from clinical trials (1343 patient-years exposure to Ferriprox monotherapy and 244 patient-years exposure to Ferriprox and deferoxamine) showed statistically significant (p &lt; 0.05) differences in the incidence of adverse reactions based on System Organ Class for “Cardiac disorders", "Musculoskeletal and connective tissue disorders” and "Renal and urinary disorders".
Podaci iz objedinjene baze podataka o sigurnosti primjene dobivenih iz kliničkih ispitivanja (1343 bolesnik-godina izloženosti monoterapiji Ferriproxom i 244 bolesnik-godina izloženosti Ferriproxu i deferoksaminu) pokazali su statistički značajne (p &lt; 0,05) razlike u incidenciji nuspojava koje se temelje na klasifikaciji organskih sustava za "srčane poremećaje", "poremećaje mišićno-koštanog sustava i vezivnog tkiva" te "poremećaja bubrega i mokraćnog sustava".
Data in patients with creatinine clearance &lt; 30 mL/min are limited and there are no data for patients on dialysis.
Podaci za bolesnike s klirensom kreatinina &lt; 30 ml/min su ograničeni, dok podataka za bolesnike na dijalizi nema.
Data in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min) are limited and there are no data for patients on dialysis, therefore riociguat is not recommended in these patients.
Podaci za bolesnike s teškim oštećenjem funkcije bubrega (klirens kreatinina &lt; 30 ml/min) su ograničeni, a podataka za bolesnike na dijalizi nema, pa se stoga riocigvat ne preporučuje u tih bolesnika.
Data in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min) are limited and there are no data for patients on dialysis.
Podaci za bolesnike s teškim oštećenjem funkcije bubrega (klirens kreatinina &lt; 30 ml/min) su ograničeni, a podataka za bolesnike na dijalizi nema.
Data in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min) are limited and there are no data for patients on dialysis.
Podaci za bolesnike s teškim oštećenjem funkcije bubrega (klirensom kreatinina &lt; 30 ml/min) su ograničeni, a podataka za bolesnike na dijalizi nema.
Data on patients &gt; 65 years are limited to &lt; 1.6% of the studied population.
Podaci o bolesnicima starijima od 65 godina su ograničeni na &lt; 1,6% ispitivane populacije.
Data on safety of Spectrila in infants &lt; 1 year of age is limited.
Ograničeni su podaci o primjeni Spectrile u dojenčadi mlađe od 1 godine.
Data on the effects of Dexdor in patients with heart rate &lt; 60 are very limited and particular care should be taken with such patients.
Podaci o učincima lijeka Dexdor u bolesnika sa srčanom frekvencijom &lt; 60 su vrlo ograničeni pa je kod takvih bolesnika potreban poseban oprez.
Data on time to worsening of neurological status favoured TMZ over procarbazine as did data on time to worsening of performance status (decrease to a KPS of &lt; 70 or a decrease by at least 30 points).
Podaci o vremenu do pogoršanja neurološkog statusa kao i o vremenu do pogoršanja izvedbenog statusa (KPS smanjen na &lt; 70 bodova ili za najmanje 30 bodova) bolji su za TMZ u odnosu na prokarbazin.
Data on treatment for &gt; 24 hours is not available.
Podaci o liječenju &gt; 24 sata nisu dostupni.
Data on very elderly patients ( &gt; 75 years) are very limited (see sections 4.8 and 5.1).
Podaci o primjeni u znatno starijih bolesnika ( &gt; 75 godina) vrlo su ograničeni (vidjeti dijelove 4.8 i 5.1).
Date of first authorisation: &lt; date of EU Decision &gt;
Datum prvog odobrenja: &lt; datum Odluke EU &gt;
Day 6 &amp; thereafter
6. dan i nadalje
Decrease of elevated intraocular pressure in paediatric patients aged 2 months to &lt; 18 years with ocular hypertension or paediatric glaucoma (see section 5.1).
Snižavanje povišenog intraokularnog tlaka u pedijatrijskih bolesnika u dobi od 2 mjeseca do &lt; 18 godina s očnom hipertenzijom ili pedijatrijskim glaukomom (vidjeti dio 5.1).
Decreases &lt; LLN* ( &lt; 90 ml/min)
smanjen &lt; DGN-a* ( &lt; 90 ml/min)
Decreases &gt; 10% from the normal reference range at baseline were observed for carbon dioxide (15.1%), bicarbonate (13.3%), and creatinine (10.7%) concentrations.
Uočeni su padovi od &gt; 10 % u odnosu na normalan raspon referentnih vrijednosti kod početne vrijednosti za koncentracije ugljikova dioksida (15,1 %), bikarbonata (13,3 %) i kreatinina (10,7 %).
Decreases in haemoglobin to &lt; 10 g/dL and &lt; 8.5 g/dL during treatment were experienced by 39% and 13% of patients treated with ledipasvir/sofosbuvir with ribavirin, respectively.
Tijekom liječenja, hemoglobin se snizio na &lt; 10 g/dl u 39 % odnosno na &lt; 8,5 g/dl u 13 % pacijenata liječenih ledipasvirom/sofosbuvirom s ribavirinom.
Decreases in white blood cell counts of &lt; 3.0 x 109/L were observed in 7% of patients receiving Plegridy and in 1% receiving placebo.
Smanjenja broja bijelih krvnih stanica od &lt; 3,0 x 109/l opažena su u 7% bolesnika koji su primali Plegridy i u 1% koji su primali placebo.
Decreases in white blood cell counts of &lt; 3.0 x 109/L were observed in 7% of patients receiving Plegridy and in 1% receiving placebo.
Smanjenje broja bijelih krvnih stanica od &lt; 3,0 x 109/l opažena su u 7% bolesnika koji su primali Plegridy i u 1% koji su primali placebo.
Defined as a Mayo score ≤ 2 points, with no individual subscore &gt; 1
Definirano kao Mayo rezultat ≤ 2 boda, pri čemu nijedan podrezultat nije &gt; 1
Delamanid exposure remained unchanged ( &lt; 25% difference) with anti- HIV medicines tenofovir and efavirenz but was slightly increased with the combination anti-HIV medicine containing lopinavir/ritonavir.
Izloženost delamanidu je ostala nepromijenjena ( &lt; 25% razlike) s lijekovima protiv HIV-a, tenofovirom i efavirenzom, ali je blago povećana u kombinaciji s lijekovima protiv HIV-a koji sadrže lopinavir/ritonavir.
Delay of next cycle due to persistent neutropenia2 (Nadir ANC &lt; 1500/mm3)
Odgoda sljedećeg ciklusa zbog ustrajne neutropenije2 (najniža vrijednost ABN
Delay treatment until improvement or resolution, and until neutrophil count is &gt; 1,500 cells/mm3, then reduce cabazitaxel dose from 25 mg/m2 to 20 mg/m2.
Odgoditi liječenje do poboljšanja ili oporavka te dok broj neutrofila ne dosegne &gt; 1500 stanica/mm3, a zatim smanjiti dozu kabazitaksela s 25 mg/m2 na 20 mg/m2.
Delayed post-contrast or equilibrium images ( &gt; 5 minutes after dosing) assist in the characterization of lesions, e.g. the centre of a metastasis may accumulate contrast in the interstitial space of the lesion and become hyperintense to the normal liver.
Odgođeni post-kontrastni ili prikazi nakon raspodjele kontrasta ( &gt; 5 minuta nakon doziranja) pomažu pri karakterizaciji lezija, npr. središte metastaze može nakupljati kontrast u intersticijskom prostoru i izgledati puno izraženije u odnosu na normalnu jetru.
Dermatitis; Rash erythematous (G3/4: &lt; 1%);
dermatitis eritematozni osip (G 3/4:
Descovy should not be initiated in patients with estimated CrCl &lt; 30 mL/min as there are limited data available regarding the use of Descovy in this population (see sections 5.1 and 5.2).
Primjena lijeka Descovy se ne smije započeti u bolesnika s procijenjenim CrCl &lt; 30 ml/min budući da su dostupni ograničeni podaci o primjeni lijeka Descovy u ovoj populaciji (vidjeti dijelove 5.1 i 5.2).
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu
Detaljnije informacije o ovom lijeku dostupne su na web stranici Europske agencije za lijekove: http://www.ema.europa.eu &lt; , i na web stranici {naziv MS agencije (poveznica)} &gt; .
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu &lt; , and on the website of {name of MS Agency (link)} &gt; . &lt; There are also links to other websites about rare diseases and treatments.
Detaljnije informacije o ovom lijeku dostupne su na internetskoj stranici Europske agencije za lijekove: http://www.ema.europa.eu &lt; , i na internetskoj stranici {naziv nadležnog tijela države članice (link)} &gt; . &lt; Tamo se također nalaze poveznice na druge internetske stranice o rijetkim bolestima i liječenjima istih.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/
Detaljne informacije o ovom veterinarsko-medicinskom proizvodu su dostupne na web stranici Europske agencije za lijekove (EMA) http://www.ema.europa.eu/. &gt;
Dextromethorphan did not inhibit ( &lt; 20% inhibition) any of the tested isoenzymes: CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or
Dekstrometorfan u koncentracijama do 5 µM nije inhibirao ( &lt; 20% inhibicije) nijedan od ispitanih izoenzima: CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 ili CYP3A4 u mikrosomima ljudske jetre.
Diabetes mellitus, renal impairment, age ( &gt; 70 years)
Šećerna bolest, poremećaj rada bubrega, dob ( &gt; 70 godina).
Diabetes mellitus, renal impairment, age ( &gt; 70 years)
Dijabetes melitus, oštećenje bubrega, dob ( &gt; 70 godina)
Diabetes mellitus, renal impairment, age ( &gt; 70 years)
Dijabetes melitus, oštećenje bubrega, dob ( &gt; 70 godina).
Diabetes mellitus, renal impairment, age ( &gt; 70 years)
Dijabetes melitus, poremećaj funkcije bubrega, dob ( &gt; 70 godina).
Diabetes mellitus, renal impairment, age ( &gt; 70 years)
Dijabetes melitus, poremećaj rada funkcije bubrega, dob ( &gt; 70 godina).
Diabetes mellitus, renal impairment, age ( &gt; 70 years).
Dijabetes melitus, poremećaj rada bubrega, dob ( &gt; 70 godina).
Diabetes Mellitus: Frequency will depend on the presence or absence of risk factors (fasting blood glucose ≥ 5.6 mmol/L, BMI &gt; 30kg/m2, raised triglycerides, history of hypertension).
šećerna bolest: učestalost će ovisiti o prisutnosti ili odsutnosti faktora rizika (glukoza u krvi natašte ≥ 5.6 mmol/l, BMI &gt; 30kg/m2, povišeni trigliceridi, hipertenzija u anamnezi).
diabetic ketoacidosis, diabetic pre-coma; moderate and severe renal impairment (creatinine clearance &lt; 60 ml/min; eGFR &lt; 60 ml/min/1.73 m2) (see sections 4.2, 4.4 and 5.2);
dijabetičkom ketoacidozom, dijabetičkom pretkomom; s umjerenim i teškim oštećenjem bubrega (klirens kreatinina &lt; 60 ml/min; eGFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.2, 4.4 i 5.2);
Dialysis may not be effective in removing tolvaptan because of its high binding affinity for human plasma protein ( &gt; 98%).
Dijaliza možda neće biti učinkovita u uklanjanju tolvaptana zbog njegovog visokog afiniteta vezanja za ljudske proteine plazme ( &gt; 98%).
Diameter &lt; 6 mm at any time
Promjer &lt; 6 mm u bilo kojem trenutku
Diameter &lt; 6 mm at cortical clean-up
Promjer &lt; 6 mm u trenutku uklanjanja kortikalnog materijala
Diarrhoea can occur early (onset in ≤ 24 hours after starting ONIVYDE) or late ( &gt; 24 hours) (see section 4.8).
Proljev se može pojaviti rano (pojava ≤ 24 nakon započinjanja primjene lijeka ONIVYDE) ili kasno ( &gt; 24 sata) (vidjeti dio 4.8).
Difference in least square means, p0.0001/0.0004 based on two-sided stratified Cochran-Mantel- Haenszel test
Razlika u metodi najmanjih kvadrata, p &lt; 0,0001/0,0004 na temelju dvosmjernog stratificiranog Cochran-Mantel-Haenszel testa
Differences between the 2 groups were statistically significant (p &lt; 0.05) for all criteria listed.
Razlike između 2 skupine bile su statistički značajne (p &lt; 0,05) za sva navedena mjerila.
Differences between the 2 groups were statistically significant (p &lt; 0.05) for all criteria listed.
Razlike između 2 grupe bile su statistički značajne (p &lt; 0,05) za sve navedene kriterije.
Differences between the 2 groups were statistically significant (p &lt; 0.05) for all criteria listed.
Razlike između dvije grupe bile su statistički značajne (p &lt; 0,05) za sve navedene kriterije.
Dilution to a final concentration &lt; 0.2 MU/ml (2 μg/ml) is not recommended at any time.
Nikad se ne preporučuje razrijediti lijek do konačne koncentracije &lt; 0,2 MU/ml (2 μg/ml).
Dilution to a final concentration &lt; 0.2 MU/ml (2 μg/ml) is not recommended at any time.
Nikada se ne preporučuje razrjeđivanje do konačne koncentracije &lt; 0,2 MU/ml (2 μg/ml).
Discontinuation of treatment due to non-procedural bleeding was more common for ticagrelor (2.9%) than for clopidogrel (1.2%; p &lt; 0.001).
Prekid liječenja zbog neproceduralnog krvarenja je bio češći za tikagrelor (2,9%) nego za klopidogrel (1,2%; p &lt; 0,001).
Discontinuation of Zinbryta due to infections was &lt; 1%.
Prekid liječenja Zinbrytom zbog infekcija bio je &lt; 1%.
Discontinuations due to elevated hepatic transaminases were &lt; 1% and similar in patients treated with Tecfidera or placebo.
Prekid sudjelovanja zbog povišenih razina jetrenih transaminaza bio je &lt; 1% i sličan u bolesnika liječenih Tecfiderom ili placebom.
Discontinue ribavirin if CrCL &lt; 50ml/min
Obustaviti davanje ribavirina ako je CrCL &lt; 50 ml/min
Discontinue treatment for 1 to 2 weeks until values have improved and albumin &gt; 2.5 g/dl, then decrease dose by 0.5 mg/kg.
Prekinuti terapiju na 1 do 2 tjedna dok se vrijednosti ne poprave i albumin &gt; 2,5 g/dl, zatim smanjivati dozu po 0,5 mg/kg.
Discontinue treatment until &lt; 1.25 X upper normal limit, then decrease dose by 0.5 mg/kg
Prekinuti terapiju do &lt; 1,25 puta gornja normalna granica, zatim smanjivati dozu po 0,5 mg/kg
Discontinue treatment until &gt; 1.5 g/dl and clinical signs normal, then decrease dose by 0.5 mg/kg
Prekinuti terapiju do &gt; 1,5 g/dl i normalni klinički simptomi, zatim smanjivati dozu po 0,5 mg/kg
Discontinue treatment until &gt; 1.5 g/dl and clinical signs normal, then decrease dose by 0.5 mg/kg
Prekinuti terapiju do &gt; 1,5 g/dl i normalnih kliničkih simptoma, zatim smanjivati dozu po 0,5 mg/kg
Discontinue treatment until &gt; 1000/l and clinical signs normal, then decrease dose by 0.5 mg/kg
Prekinuti terapiju do &gt; 1000/ul i normalni klinički simptomi, zatim smanjivati dozu po 0,5 mg/kg
Discontinue treatment until &gt; 1000/l and clinical signs normal, then decrease dose by 0.5 mg/kg
Prekinuti terapiju do &gt; 1000/µl i normalnih kliničkih simptoma, zatim smanjivati dozu po 0,5 mg/kg
Discontinue treatment until &gt; 26%, then decrease dose by 0.5 mg/kg
Prekinuti terapiju do &gt; 26%, zatim smanjivati terapiju po 0,5 mg/kg
Discontinued study drug due to other reasons and last available HIV-1 RNA &lt; 50 copies/mLd
Prekid primanja ispitivanog lijeka iz drugih razloga i posljednje dostupne vrijednosti HIV-1 RNK &lt; 50 kopija/mld
Discontinued study drug due to other reasons and last available HIV-1 RNA &lt; 50 copies/mLe
Prekid primanja ispitivanog lijeka iz drugih razloga i posljednje dostupne vrijednosti HIV-1 RNK &lt; 50 kopija/mle
Disease-free survival (DFS) and overall survival (OS) constantly exceeded 1 year and were superior to historical control (DFS p &lt; 0.001; OS p &lt; 0.0001) in two studies (AJP01 and AUS01).
Preživljenje bez bolesti (DFS) i ukupno preživljenje (OS) stalno premašuju 1 godinu te su superiorni nad prethodnim kontrolama (DFS p &lt; 0,001; OS p &lt; 0,0001) u dva ispitivanja (AJP01 i AUS01).
Disease-free survival (DFS) and overall survival (OS) constantly exceeded 1 year and were superior to historical control (DFS p &lt; 0.001; OS p &lt; 0.0001) in two studies (AJP01 and AUS01).
Preživljenje bez bolesti (DFS) i ukupno preživljenje (OS) stalno su premašivali 1 godinu te su bili superiorni nad povijesnim kontrolama (DFS p &lt; 0,001; OS p &lt; 0,0001) u dva ispitivanja (AJP01 i AUS01).
Disease-free survival (DFS) and overall survival (OS) constantly exceeded 1 year and were superior to historical control (DFS p &lt; 0.001; OS p &lt; 0.0001) in two studies (AJP01 and AUS01).
Preživljenje bez bolesti (DFS) i ukupno preživljenje (OS) stalno su premašivali 1 godinu te su bili superiorni povijesnojkontroli (DFS p &lt; 0,001; OS p &lt; 0,0001) u dva ispitivanja (AJP01 i AUS01).
Disease-free survival (DFS) and overall survival (OS) constantly exceeded 1 year and were superior to historical control (DFS p &lt; 0.001; OS p &lt; 0.0001) in two studies (AJP01 and AUS01).
Preživljenje bez bolesti (DFS) i ukupno preživljenje (OS) stalno su premašivali1 godinu te su bili superiorni povijesnojkontroli (DFS p &lt; 0,001; OS p &lt; 0,0001) u dva ispitivanja (AJP01 i AUS01).
Disease-free survival (DFS) and overall survival (OS) constantly exceeded 1 year and were superior to historical control (DFS p &lt; 0.001; OS p &lt; 0.0001) in two studies (AJP01 and AUS01).
Preživljenje bez znakova (DFS) i ukupno preživljenje (OS) stalno premašuju 1 godinu te su superiorni nad prethodnim kontrolama (DFS p &lt; 0,001; OS p &lt; 0,0001) u dva ispitivanja (AJP01 i AUS01).
DNA &lt; 8 log10 IU/ml
HBV DNK &lt; 8 log10 IU/ml
Do not administer trastuzumab emtansine until AST/ALT recovers to Grade ≤ 2 ( &gt; 2.5 to &lt; 5 x ULN), and then dose reduce (see table 1).
Trastuzumab emtanzin se ne smije primjenjivati dok se AST/ALT ne vrati na vrijednost stupnja ≤ 2 ( &gt; 2,5 do &lt; 5 x GGN), a zatim dozu treba smanjiti (vidjeti Tablicu 1).
Do not administer trastuzumab emtansine until total bilirubin recovers to Grade  1 ( &gt; ULN to 1.5x ULN).
Trastuzumab emtanzin se ne smije primjenjivati dok se ukupni bilirubin ne vrati na vrijednost stupnja ≤ 1 ( &gt; GGN do 1,5 x GGN).
Do not dose until recovered to grade &lt; 2 and reduce dose by 25% for all subsequent doses.
Nemojte primijeniti dozu prije oporavka do &lt; 2. stupnja toksičnosti i smanjite sve sljedeće doze za 25%.
Do not dose until recovered to grade &lt; 2 and reduce dose by 25% for all subsequent doses.
Nemojte primijeniti dozu prije oporavka na &lt; 2. stupnja toksičnosti i smanjite sve sljedeće doze za 25%.
Do not overheat &gt; 37 °C.
Ne pregrijavati &gt; 37 °C.
Do not use in dogs suffering from liver impairment, defined as AST or ALT &gt; 3 x Upper Limit of Normal (ULN).
Ne primjenjivatina psima koji imaju oštećenje jetre, određeno kao povišenje AST ili ALT &gt; 3 x gornja granica normale (GGN).
Do not use in dogs suffering from renal function impairment, defined as Urinary Protein Creatinine (UPC) ratio &gt; 2 or albumin &lt; 1 x Lower Limit of Normal (LLN).
Ne primjenjivati na psima koji koji imaju oštećenje bubrežne funkcije, definirano kao porast omjer bjelančevina i kreatinina u mokraći (Urinary Protein Creatinine – UPC ratio) &gt; 2 ili pad albumina &lt; 1 x donja granica normale (DGN).
Do not use in dogs with anaemia (haemoglobin &lt; 10 g/dl).
Ne ne primjenjivati na anemičnim psima (hemoglobin &lt; 10 g/dl).
Do not use in dogs with neutropenia defined as absolute neutrophil count &lt; 2,000 /mm3.
Ne primjenjivati napsima s neutropenijom ako je ukupni broj neutrofila &lt; 2.000 /mm3.
Docetaxel is highly protein bound ( &gt; 95%).
Docetaksel se izrazito veže za proteine ( &gt; 95%).
Does the patient have a systolic blood pressure &lt; 100 mm Hg?
Ima li bolesnik sistolički krvni tlak &lt; 100 mm Hg?
Dog (11-22 kg)
Pas ( &gt; 11 - 22 kg)
Dog (22-50 kg)
Pas ( &gt; 22 - 50 kg)
Dog (4.5-11 kg)
Pas ( &gt; 4,5 - 11 kg)
Dogs 2–3.5 kg Dogs &gt; 3.5–7.5 kg Dogs &gt; 7.5–15 kg Dogs &gt; 15–30 kg Dogs &gt; 30–60 kg
Psi 2–3,5 kg Psi &gt; 3,5–7,5 kg Psi &gt; 7,5–15 kg Psi &gt; 15–30 kg Psi &gt; 30–60 kg
Dogs 2–4 kg Dogs &gt; 4–10 kg Dogs &gt; 10–25 kg Dogs &gt; 25-50 kg
Psi od 2–4 kg Psi &gt; 4–10 kg Psi &gt; 10–25 kg Psi &gt; 25–50 kg
Dolutegravir has a &lt; 10 fold change against 94% of the 705 clinical isolates.
Vrijednost promjene za dolutegravir iznosila je &lt; 10 u 94% od 705 kliničkih izolata.
Dolutegravir is highly bound ( &gt; 99%) to human plasma proteins based on in vitro data.
Podaci in vitro pokazuju da se dolutegravir u visokom stupnju ( &gt; 99%) veže za proteine u plazmi ljudi.
Dolutegravir is highly bound ( &gt; 99%) to human plasma proteins based on in vitro data.
Na temelju podataka in vitro, dolutegravir se u visokom stupnju ( &gt; 99%) veže za proteine u plazmi ljudi.
Dolutegravir is the predominant circulating compound in plasma; renal elimination of unchanged active substance is low ( &lt; 1% of the dose).
Dolutegravir je glavni cirkulirajući spoj u plazmi; eliminacija djelatne tvari u nepromijenjenu obliku kroz bubrege je niska ( &lt; 1% doze).
Dosage adjustments are not required in elderly patients (≥ 65 years old).
Prilagodbe doziranja u starijih bolesnika nisu potrebne ( &gt; 65 godina starosti).